Goodwin Biotechnology has partnered with Aspyrian Therapeutics to complete process development, scale-up, and cGMP manufacture of their novel Antibody Drug Conjugate (ADC). Aspyrian recently received FDA acceptance of an IND application for RM-1929, a precision targeted therapy for cancer, and will be initiating clinical trials in patients with recurrent head and neck cancer.
"The team at Goodwin Biotechnology takes great pride in partnering with our clients and advancing their biopharmaceutical candidates through the development phase and to file INDs," said SooYoung S. Lee, Ph.D., chief operating officer at Goodwin Biotechnology. "We have worked with numerous clients in the past and it always reinforces our drive and commitment when we're able to add value to our clients and their product portfolio."
"I have found that working with the team at Goodwin Biotechnology has been a great pleasure," said Miguel Garcia-Guzman, Ph.D., president and chief scientific officer at Aspyrian Therapeutics. "We were originally impressed by their expertise in Bioconjugation. This perception was reinforced by the flexible and solution-oriented approach to the complexity of our project. They treated our product as theirs as they orchestrated a flexible and well-run process. This is our company's first IND submission and securing the IND was a crucial milestone for our company. It speaks about the quality, timeliness, and process economics that Goodwin Biotechnology puts into every aspect of their work."
